Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension (LIFE) study

被引：7
|
作者：
Devereux, RB
Lyle, PA
机构：
[1] Cornell Univ, Weill Med Coll, Div Cardiol, New York, NY 10021 USA
[2] Merck Res Labs, West Point, PA 19486 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2004年 / 5卷 / 11期
关键词：
albuminuria; angiotensin II; angiotensin-receptor antagonist; antihypertensive agents; diabetes mellitus; hypertension; isolated systolic hypertension; left ventricular hypertrophy; Losartan; stroke; uric acid;
D O I：
10.1517/14656566.5.11.2311
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class. It has been approved for the treatment of hypertension, and may be used alone or in combination with other anti hypertensive agents. Based on the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. Based on the Reduction of Endpoints in NOW with the Angiotensin II Antagonist Losartan (RENAAL) study, losartan is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria, in patients with Type 2 diabetes. The focus of this review is the LIFE study.
引用
收藏
页码：2311 / 2320
页数：10
相关论文
共 50 条
  • [41] Effect of losartan compared to atenolol on cardiovascular mortality and morbidity in high and low risk patients with left ventricular hypertrophy.: A losartan intervention for endpoint reduction -: The LIFE study
    Franklin, SS
    Wachtell, K
    Papademetriou, V
    Olsen, MH
    Ibsen, H
    Kjeldsen, SE
    Devereux, RB
    Julius, S
    Dahlöf, B
    JOURNAL OF HYPERTENSION, 2003, 21 : S67 - S67
  • [42] Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    B Dahlöf
    T A Burke
    K Krobot
    G W Carides
    J M Edelman
    R B Devereux
    H-C Diener
    Journal of Human Hypertension, 2004, 18 : 367 - 373
  • [43] Population impact of losartan use on stroke in the European Union (EU):: Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Dahlöf, B
    Burke, TA
    Krobot, K
    Carides, GW
    Edelman, JM
    Devereux, RB
    Diener, HC
    JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (06) : 367 - 373
  • [44] Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study
    Cicala, Silvana
    de Simone, Giovanni
    Gerdts, Eva
    Dahlof, Bjorn
    Lindholm, Lars H.
    Kjeldsen, Sverre E.
    Devereux, Richard B.
    JOURNAL OF HYPERTENSION, 2010, 28 (06) : 1134 - 1140
  • [45] An analysis of cholesterol control and statin use in the Losartan intervention for Endpoint reduction in hypertension study
    Kristianson, K
    Fyhrquist, F
    Devereux, RB
    Kjeldsen, SE
    Lindholm, LH
    Lyle, PA
    Nieminen, MS
    Snapinn, SM
    CLINICAL THERAPEUTICS, 2003, 25 (04) : 1186 - 1199
  • [46] In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients -: The Losartan intervention for Endpoint Reduction in Hypertension (LIFE) study
    Okin, Peter M.
    Devereux, Richard B.
    Harris, Katherine E.
    Jern, Sverker
    Kjeldsen, Sverre E.
    Lindholm, Lars H.
    Dahloef, Bjoern
    HYPERTENSION, 2007, 50 (05) : 984 - 990
  • [47] Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
    Lindholm, LH
    Ibsen, H
    Borch-Johnsen, K
    Olsen, MH
    Wachtell, K
    Dahlöf, B
    Devereux, RB
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Julius, S
    Kjeldsen, SE
    Kristianson, K
    Lederballe-Pedersen, O
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    Aurup, P
    Edelman, JM
    Snapinn, S
    JOURNAL OF HYPERTENSION, 2002, 20 (09) : 1879 - 1886
  • [48] Does losartan reduce the incidence of revascularizations in patients with hypertension and electrocardiographic left ventricular hypertrophy?: The LIFE Study
    Olsen, MH
    Wachtell, K
    Dahlöf, B
    Devereux, RB
    Ibsen, H
    Kjeldsen, SE
    Lindholm, L
    Nieminen, MS
    EUROPEAN HEART JOURNAL, 2004, 25 : 328 - 328
  • [49] Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)Lessons learned for losartan: An "old dog playing good tricks"
    Katsiki, Niki
    Tsioufis, Konstantinos
    Ural, Dilek
    Volpe, Massimo
    JOURNAL OF CLINICAL HYPERTENSION, 2018, 20 (08): : 1153 - 1159
  • [50] Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension
    Picca, M
    Agozzino, F
    Pelosi, G
    ADVANCES IN THERAPY, 2004, 21 (02) : 76 - 86
12345